Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials

In two phase 3 trials, the SGLT2 inhibitor ertugliflozin for the treatment of type 2 diabetes that is uncontrolled with metformin alone or with sitagliptin demonstrated safety and efficacy at 52 weeks.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news